Viewing Study NCT06093061


Ignite Creation Date: 2025-12-24 @ 11:48 AM
Ignite Modification Date: 2026-01-01 @ 9:38 PM
Study NCT ID: NCT06093061
Status: RECRUITING
Last Update Posted: 2025-05-11
First Post: 2023-10-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
Sponsor: National Cancer Centre, Singapore
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module